Submit your email to push it up the queue
Daiichi Sankyo, Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States, with significant operations across Europe, Asia, and other regions. Founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, Limited, the company has established itself as a leader in innovative medicines, particularly in oncology, cardiovascular, and vaccine development. Daiichi Sankyo is renowned for its unique approach to drug discovery and development, leveraging advanced technologies to create targeted therapies. Its core products, including the groundbreaking cancer treatment, have positioned the company as a key competitor in the pharmaceutical market. With a commitment to improving patient outcomes, Daiichi Sankyo continues to achieve notable milestones, solidifying its reputation as a trusted name in healthcare.
How does Daiichi Sankyo, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Daiichi Sankyo, Inc.'s score of 55 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Daiichi Sankyo, Inc., headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Daiichi Sankyo Company, Limited, which may influence its climate commitments and initiatives. While there are no documented reduction targets or achievements from Daiichi Sankyo, Inc. itself, it is important to note that the parent company, Daiichi Sankyo Company, Limited, may have established climate initiatives that could impact its subsidiaries. The emissions data and climate strategies from Daiichi Sankyo Company, Limited are cascaded to Daiichi Sankyo, Inc. at a level 1 relationship. Daiichi Sankyo Company, Limited is involved in various climate initiatives, including the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which may guide the climate commitments of its subsidiaries. However, specific targets or commitments from these initiatives have not been detailed for Daiichi Sankyo, Inc. In summary, while Daiichi Sankyo, Inc. does not currently report emissions data or specific reduction targets, it is part of a corporate family that may have broader climate commitments through its parent company.
Access structured emissions data, company-specific emission factors, and source documents
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 182,519,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 290,715,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 5,704,000 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Daiichi Sankyo, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.